By: 6 October 2014
Sheffield artificial bone manufacturer expects to see £1 million turnover after growth

A Sheffield company that makes artificial bone used by surgeons in more than 50 countries is expanding.

Ceramisys manufactures ReproBone, which is used as a synthetic bone graft material. The product, which comes in block, granular or paste form, is used instead of, or to supplement, a patient’s own bone in orthopaedic surgery.

As reported by Bdaily Business News, ReproBone is already used on every continent in the world and in the last month alone the company has taken on distributors in five new countries, with turnover expected to exceed £1 million this year.

Last year Ceramisys moved to a purpose-built facility in Hillsborough, where it is carrying out new product research and looking to take on more staff.

The expansion is being backed by Creative Sheffield, which has helped Ceramisys build relationships with leading surgeons, giving the company more standing in the medical device market.

Ceramisys was founded in 2001 by Wayne Austin, a former Sheffield University chemistry graduate. The company’s first product gained its regulatory approval in 2003, with the full product range now approved for use in most countries. This is similar to playing casino games in Cool Cat Casino sites from here in cool cat casino online sites.

ReproBone is used to repair bone in surgical procedures, including non-healing fractures, defects caused by removal of bone tumours, revision hip replacements and deformities. The material helps regenerate the bone and, within a few months, it is broken down and replaced by new healthy bone.

Austin said: “The main advantages of the ReproBone products are that patients don’t need to have a second operation site to collect bone to fill the defect, so it takes away the risk and trauma associated with that. From the surgeon’s point of view it is easy to use and available in unlimited quantities.

“It is really important for us to be held in high regard by surgeons and one of the barriers to growth we initially encountered was gaining confidence in the product from healthcare providers across the world.

“Being recognised by opinion leaders in the orthopaedic field is extremely important in order to compete with the big multinationals and increase our global market share.”